XML 27 R16.htm IDEA: XBRL DOCUMENT v3.10.0.1
10. Segment Information
 6 Months Ended
Jun. 30, 2018
Segment Reporting [Abstract]  
Segment Information EGMENT INFORMATION

Information regarding industry segments for the three months ended June 30, 2018 and 2017 is as follows (in millions):
 
 
Life
Science
 
Clinical
Diagnostics
 
Other
Operations
 
 
 
 
 
 
 
Segment net sales 
2018
$
217.8

 
$
354.0

 
$
4.1

 
2017
$
179.4

 
$
322.1

 
$
3.2

 
 
 
 
 
 
 
Segment net profit (loss)
2018
$
12.2

 
$
27.8

 
$
—

 
2017
$
(22.9
)
 
$
18.5

 
$
0.2


Information regarding industry segments for the six months ended June 30, 2018 and 2017 is as follows (in millions):
 
 
Life
Science
 
Clinical
Diagnostics
 
Other
Operations
 
 
 
 
 
 
 
Segment net sales 
2018
$
415.6

 
$
704.8

 
$
7.0

 
2017
$
353.6

 
$
644.4

 
$
6.7

 
 
 
 
 
 
 
Segment net profit (loss)
2018
$
15.5

 
$
64.4

 
$
—

 
2017
$
(41.7
)
 
$
60.1

 
$
0.4



Prior year amounts have been adjusted (see Note 1 to the condensed consolidated financial statements in regard to ASU 2017-07 for pension and other postretirement benefits).

Segment results are presented in the same manner as we present our operations internally to make operating decisions and assess performance.  Net corporate operating, interest and other expense for segment results consists of receipts and expenditures that are not the primary responsibility of segment operating management and therefore are not allocated to the segments for performance assessment by our chief operating decision maker.  Interest expense is charged to segments based on the carrying amount of inventory and receivables employed by that segment. For the three and six months ended June 30, 2018 compared to the same periods in 2017, our Life Science segment had increased sales and gross profit, along with lower Research and Development expense. In addition, the Life Science segment gross margin included a $10.0 million one-time expense associated with the RainDance acquisition in the first quarter of 2017. During the second quarter of 2017, our Clinical Diagnostics segment had an asset purchase for an early stage device for $7.5 million that was recorded in Research and development expense. The following reconciles total segment profit to consolidated income before taxes (in millions):
 
Three Months Ended
 
Six Months Ended
 
June 30,
 
June 30,
 
2018
 
2017
 
2018
 
2017
Total segment profit (loss)
$
40.0

 
$
(4.2
)
 
$
79.9

 
$
18.8

Foreign currency exchange losses, net
—

 
(2.5
)
 
(1.2
)
 
(4.3
)
Net corporate operating, interest and other expense not allocated to segments
(2.2
)
 
(3.6
)
 
(4.2
)
 
(5.6
)
Change in fair market value of equity securities
286.4

 
—

 
1,102.3

 
—

Other income (expense), net
15.9

 
11.4

 
27.0

 
12.4

Consolidated income before income taxes
$
340.1

 
$
1.1

 
$
1,203.8

 
$
21.3


Prior year amounts have been adjusted (see Note 1 to the condensed consolidated financial statements in regard to ASU 2017-07 for pension and other postretirement benefits).